On April 28, 2025, Aptevo Therapeutics Inc. entered into an offering agreement with Roth Capital Partners allowing the sale of up to $2,959,952 of its common stock. Additionally, as of March 31, 2025, the company had approximately $2.1 million in cash and cash equivalents, though this figure is preliminary and subject to finalization.